



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Saul Faust**

Organisation/Company: Southampton University NHS Trust

Country: United Kingdom

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
05/2008-05/2008	GlaxoSmithKline	UK Paediatric Vaccines Advisory Board	paediatric vaccines
05/2009-05/2009	Wyeth	European Paediatric Pneumococcal Advisory Board	paediatric vaccines
11/2009-11/2009	Sanofi Pasteur MSD	Rotavirus Vaccination Advisory Board	paediatric vaccines
01/2010-01/2010	GlaxoSmith Kline	UK Paediatric Vaccines Advisory Board	paediatric vaccines
04/2010-04/2010	Pfizer	Paediatric Advisory Board	paediatric vaccines
07/2010-07/2010	GlaxoSmithKline	UK Vaccines Advisory Board	paediatric vaccines
11/2010-11/2010	Pfizer	Tigecycline Paediatric Advisory Board	antimicrobial therapy
01/2011-01/2011	Pfizer	Paediatric Vaccines Advisory Board	paediatric vaccines
03/2011-03/2011	GlaxoSmithKline	Paediatric Vaccines Advisory Board	paediatric vaccines

Classified as public by the European Medicines Agency

06/2011-06/2011	Novartis	Scientific Advisory Committee	paediatric vaccines
11/2011-11/2011	Novartis	Scientific Advisory Board	paediatric vaccines
02/2012-02/2012	GlaxoSmithKline	Nimrex European Payers Advisory Board	paediatric vaccines
05/2012-05/2012	Pfizer	Meningitis B Advisory Board	paediatric vaccines
11/2012-11/2012	Pfizer	Meningitis B Vaccines meeting	paediatric vaccines
11/2012-11/2012	Sanofi	Vaccines Advisory Board	paediatric vaccines
04/2013-04/2013	Equal convenors: Astellas, Cubist and Actelion	Meeting of experts to discuss generic issues related to C Difficile, NOT specific products. Meeting recommended further open discussions with PDCO to discuss generic issues regarding age/case definition.	
07/2013-07/2013	Pfizer	Media Medics Lounge	paediatric vaccines
05/2013-05/2013	GlaxoSmithKline	Presentation at ESPID 2013.	
01/2014-01/2014	Equal convenors: Astellas, Cubist and Actelion	Meeting of experts to discuss generic issues related to C Difficile, NOT specific products.	
03/2015-03/2015	Pfizer	Meningococcal Scientific Strategy Advisory Board	Paediatric vaccines
06/2015-06/2015	AstraZeneca	Antiviral Advisory Board	Paediatric vaccines
11/2015-10/2018	Merck Sharp & Dohme	Scientific Advisory Board	Paediatric antimicrobial
03/2015-07/2019	Pfizer	Meningococcal vaccines	Vaccine
11/2017-01/2019	Pfizer	Pneumococcal vaccines	vaccine
11/2018-11/2018	Sandoz	paediatric antimicrobials	antimicrobials
03/2018-09/2019	Sanofi	influenza vaccines	vaccines
05/2018-07/2019	Seqirus	influenza vaccines	vaccines
06/2020-12/2020	Seqirus	COVID-19 vaccine	prevention of COVID-19
10/2020-(current)	Sanofi	anti-RSV monoclonal antibody	prevention of RSV
04/2021-(current)	Janssen/J&J	COVID-19 vaccine	prevention of COVID-19
09/2021-(current)	Pfizer	COVID-19 vaccine	prevention of COVID-19

### 2.3 Strategic advisory role

No interest declared

### 2.4 Financial interests

3

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
06/2006-04/2016	Wyeth, Pfizer, GSK, Sanofi, Novartis, Roche, Cubist, Medimmune/AstraZeneca, Alios	paediatric vaccines and antimicrobials	paediatric vaccines and antimicrobials
05/2016-(current)	GSK, Pfizer, Sanofi, Alios, Janssen/J&J, Medimmune/AstraZeneca, Novavax, Regeneron	paediatric vaccines and antimicrobials	paediatric vaccines and antimicrobials
06/2020-(current)	Janssen	COVID-19 vaccine	prevention of COVID-19
11/2020-(current)	AstraZeneca	anti-COVID-19 monoclonal antibody	prevention of COVID-19
11/2020-(current)	Valneva	COVID-19 vaccine	prevention of COVID-19
10/2021-(current)	GSK-CureVac	COVID-19 vaccine	prevention of COVID-19

## 2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Pfizer	pneumococcal molecular epidemiology

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

Member of UK NIHR C4C steering committee  
 Member of UK COVID-19 RECOVERY trial steering committee, Chair of Paediatric RECOVERY working group  
 Member of UK NISEC vaccine evaluation consortium

## 2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

**CONFIDENTIALITY UNDERTAKING**

Classified as public by the European Medicines Agency

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Saul Faust
Date:	2021-12-02

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*